The purpose of this study is to find out if an investigational medication (NBTXR3) could help elderly patients with locally advanced head & neck squamous cell carcinoma who are otherwise ineligible to receive platinum-based chemotherapy. This study will help to determine the recommended dose/s of NBTXR3. The study medication is injected directly into the tumor and is activated by radiation therapy in combination with anti-PD1 therapy.
This study aims to treat your cancer and closely resembles routine care that you would receive regardless of participating in a research study. To participate in the study, you will frequently meet with a member of the study team in addition to your oncology care team. The study involves research blood draws in addition to routine blood work, a diagnostic imaging scan (ex: MRI/PET/CT Scan), a single injection of NBTXR3 into the tumor, and 3-5 sessions of radiation therapy every other day followed up with the standard of care (either Pembrolizumab or Nivolumab).
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Colette Shen
Radiation Oncology - Chapel Hill
Clinical or Medical
Interventional
Cancer (Head and Neck, Liver, Lung, Sarcoma (bone and soft tissue), Phase 1 Trials (all cancers))
18-0943
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
